MeSH term
Frequency | Condition_Probility | Female | 369 | 0.0 |
Humans | 785 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 18 | 0.0 |
Animals | 230 | 0.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Attitude of Health Personnel | 2 | 6.0 |
English Abstract | 18 | 0.0 |
Aged | 146 | 0.0 |
Immunohistochemistry | 151 | 1.0 |
Male | 187 | 0.0 |
Neoplasm Staging | 39 | 1.0 |
Base Sequence | 56 | 0.0 |
Calcium/metabolism | 5 | 0.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
In Vitro | 10 | 0.0 |
Kinetics | 14 | 0.0 |
Models, Molecular | 7 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Protein Binding | 26 | 0.0 |
Protein Conformation | 8 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 204 | 0.0 |
CA-15-3 Antigen/*genetics/metabolism | 10 | 100.0 |
Cell Differentiation | 11 | 0.0 |
Comparative Study | 78 | 0.0 |
Ovarian Neoplasms/*genetics/metabolism | 2 | 5.0 |
Protein Isoforms | 4 | 0.0 |
RNA, Messenger/metabolism | 32 | 0.0 |
Research Support, Non-U.S. Gov't | 462 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 60 | 0.0 |
Tumor Cells, Cultured | 160 | 0.0 |
Adult | 139 | 0.0 |
CA-15-3 Antigen/*metabolism | 49 | 92.0 |
Cell Count | 7 | 0.0 |
Middle Aged | 176 | 0.0 |
Prognosis | 74 | 1.0 |
Survival Analysis | 22 | 0.0 |
Survival Rate | 28 | 1.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
CA-15-3 Antigen/*genetics/*metabolism | 2 | 100.0 |
*Helicobacter pylori | 3 | 2.0 |
Molecular Sequence Data | 177 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Reference Values | 19 | 0.0 |
Aged, 80 and over | 68 | 0.0 |
CA-15-3 Antigen/biosynthesis | 6 | 54.0 |
Mucins/*biosynthesis | 18 | 47.0 |
Paget's Disease, Extramammary/*metabolism/pathology | 3 | 60.0 |
Penis/metabolism/pathology | 2 | 100.0 |
Scrotum/metabolism/pathology | 2 | 100.0 |
Tumor Markers, Biological/*biosynthesis | 4 | 4.0 |
Vulva/metabolism/pathology | 2 | 100.0 |
Antigen Presentation | 5 | 1.0 |
Antigens, Neoplasm/*immunology | 12 | 7.0 |
CA-15-3 Antigen/immunology | 7 | 87.0 |
Cancer Vaccines/*immunology | 9 | 16.0 |
Carcinoembryonic Antigen/immunology | 2 | 14.0 |
Cells, Cultured | 33 | 0.0 |
Cytokines/secretion | 4 | 5.0 |
Cytotoxicity, Immunologic | 14 | 1.0 |
HLA-A2 Antigen/*immunology | 4 | 18.0 |
Lymphocyte Activation | 20 | 0.0 |
Neoplasm Proteins/immunology | 4 | 11.0 |
Recombinant Fusion Proteins/immunology | 5 | 4.0 |
T-Lymphocytes, Cytotoxic/immunology | 18 | 4.0 |
Amino Acid Sequence | 135 | 0.0 |
Breast Neoplasms/metabolism/*pathology | 5 | 5.0 |
CA-15-3 Antigen/*chemistry/metabolism | 2 | 100.0 |
Glycosylation | 80 | 8.0 |
Lung/*metabolism | 3 | 3.0 |
*Neoplasm Metastasis | 3 | 3.0 |
Protein Processing, Post-Translational | 7 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Tumor Cells, Cultured/metabolism/pathology | 2 | 4.0 |
Antigens, CD/biosynthesis | 2 | 0.0 |
Breast Neoplasms/*immunology/pathology | 4 | 16.0 |
Cell Division | 18 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 22 | 0.0 |
Estradiol/pharmacology | 4 | 1.0 |
Glucosamine/metabolism | 5 | 19.0 |
Tritium | 3 | 1.0 |
CA-15-3 Antigen/metabolism | 14 | 43.0 |
Helicobacter Infections/*metabolism | 2 | 16.0 |
Immunoenzyme Techniques | 51 | 1.0 |
Mucins/*metabolism | 45 | 45.0 |
Analysis of Variance | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Neoplasm Proteins/analysis | 6 | 1.0 |
CD8-Positive T-Lymphocytes/metabolism | 2 | 2.0 |
Carcinoma, Basal Cell/metabolism/pathology | 2 | 28.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 2 | 5.0 |
Eyelid Neoplasms/*metabolism/pathology | 2 | 66.0 |
Alternative Splicing | 2 | 0.0 |
Biotinylation | 3 | 2.0 |
Blotting, Western | 47 | 0.0 |
CA-15-3 Antigen/*chemistry/*metabolism | 2 | 100.0 |
Cell Line | 48 | 0.0 |
Cytoplasm/metabolism | 11 | 1.0 |
Dimerization | 3 | 0.0 |
Epithelial Cells/metabolism | 13 | 4.0 |
Precipitin Tests | 13 | 0.0 |
Protein Structure, Tertiary | 14 | 0.0 |
RNA/metabolism | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 56 | 0.0 |
Time Factors | 32 | 0.0 |
Cancer Vaccines/*immunology/therapeutic use | 3 | 75.0 |
*Immunotherapy | 12 | 7.0 |
Antigens, Tumor-Associated, Carbohydrate/analysis | 3 | 15.0 |
CA-15-3 Antigen/chemistry/genetics/*physiology | 2 | 100.0 |
Cadherins/genetics/*physiology | 2 | 100.0 |
Cell Adhesion | 14 | 1.0 |
Mice | 155 | 0.0 |
Mice, SCID | 11 | 1.0 |
Mutation | 11 | 0.0 |
Neoplasm Circulating Cells | 2 | 7.0 |
Oligosaccharides/analysis | 3 | 12.0 |
Blotting, Northern | 37 | 0.0 |
CA-15-3 Antigen/genetics/*metabolism | 14 | 93.0 |
In Situ Hybridization | 36 | 1.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Mucins/genetics/*metabolism | 17 | 44.0 |
Antibodies, Monoclonal/therapeutic use | 4 | 2.0 |
Cancer Vaccines/therapeutic use | 4 | 33.0 |
Dendritic Cells/immunology | 5 | 3.0 |
Immunity, Cellular | 9 | 1.0 |
Immunotherapy/*methods | 10 | 7.0 |
CA-15-3 Antigen/analysis | 15 | 24.0 |
Lymphatic Metastasis | 23 | 2.0 |
Mucins/*analysis | 11 | 28.0 |
Neoplasm Invasiveness | 28 | 2.0 |
Neoplasm Proteins/metabolism | 7 | 1.0 |
Treatment Outcome | 11 | 0.0 |
Tumor Markers, Biological/*metabolism | 8 | 1.0 |
Gene Expression | 48 | 0.0 |
Mucins/biosynthesis/*genetics | 6 | 35.0 |
Neoplasm Proteins/biosynthesis/genetics | 7 | 5.0 |
RNA, Messenger/genetics/metabolism | 12 | 0.0 |
Tumor Markers, Biological/biosynthesis/genetics | 2 | 14.0 |
Antigens, Tumor-Associated, Carbohydrate/*analysis | 3 | 10.0 |
Follow-Up Studies | 9 | 0.0 |
Gangliosides/analysis | 2 | 40.0 |
Mucins/analysis | 12 | 33.0 |
Predictive Value of Tests | 8 | 0.0 |
Breast Neoplasms/*metabolism | 16 | 5.0 |
Carbohydrate Conformation | 4 | 3.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Peptide Fragments/*genetics/metabolism | 2 | 15.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 4 | 1.0 |
Spectrum Analysis, Mass | 5 | 0.0 |
Tandem Repeat Sequences | 11 | 7.0 |
3T3 Cells | 3 | 0.0 |
Antibody Affinity | 5 | 2.0 |
CA-15-3 Antigen/genetics/immunology/*metabolism | 6 | 100.0 |
CHO Cells | 7 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
Endocytosis | 2 | 0.0 |
Flow Cytometry | 39 | 0.0 |
Genetic Vectors/genetics | 3 | 1.0 |
Hamsters | 15 | 0.0 |
Microscopy, Confocal | 9 | 0.0 |
Transfection | 52 | 0.0 |
Conjunctiva/*metabolism | 3 | 21.0 |
Goblet Cells/*metabolism | 2 | 33.0 |
Mucins/*physiology | 5 | 38.0 |
Tears/metabolism | 3 | 42.0 |
CA-15-3 Antigen/biosynthesis/*genetics | 7 | 100.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Disease Progression | 21 | 0.0 |
*Gene Expression Regulation | 7 | 0.0 |
Gene Expression Regulation, Neoplastic | 24 | 1.0 |
Mice, Inbred C57BL | 30 | 0.0 |
Mice, Transgenic | 29 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Species Specificity | 5 | 0.0 |
Biological Markers/analysis | 7 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 7 | 3.0 |
Gastric Mucin/*metabolism | 3 | 37.0 |
Paget's Disease, Mammary/*metabolism/pathology | 2 | 100.0 |
Chemotherapy, Adjuvant | 2 | 0.0 |
Neoplasm Invasiveness/pathology | 4 | 6.0 |
Prospective Studies | 8 | 0.0 |
Tumor Markers, Biological/*analysis | 30 | 3.0 |
CA-125 Antigen/*blood | 2 | 18.0 |
CA-15-3 Antigen/*blood | 8 | 72.0 |
Logistic Models | 3 | 0.0 |
Sensitivity and Specificity | 24 | 0.0 |
Tumor Markers, Biological/*blood | 10 | 2.0 |
Cadherins/*metabolism | 3 | 4.0 |
Gastrectomy | 2 | 3.0 |
Peptide Fragments/*metabolism | 9 | 6.0 |
Antibody Formation | 8 | 1.0 |
CA-15-3 Antigen/*genetics/*immunology | 3 | 75.0 |
Dendritic Cells/*immunology | 6 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 42 | 1.0 |
Injections, Subcutaneous | 3 | 0.0 |
T-Lymphocytes/immunology | 12 | 0.0 |
CA-15-3 Antigen/*analysis/genetics | 8 | 88.0 |
Proto-Oncogene Proteins/*analysis/genetics | 2 | 6.0 |
CA-15-3 Antigen/chemistry/*immunology | 9 | 90.0 |
COS Cells | 6 | 0.0 |
Histocompatibility Antigens Class I/immunology | 2 | 1.0 |
Immune Tolerance | 8 | 2.0 |
Immunodominant Epitopes | 2 | 14.0 |
*Immunotherapy, Adoptive | 3 | 4.0 |
Mice, Inbred CBA | 2 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 26 | 4.0 |
Genetic Vectors | 7 | 0.0 |
Breast Neoplasms/metabolism | 9 | 7.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Gene Expression Regulation | 14 | 0.0 |
Antibody Specificity | 26 | 1.0 |
DNA Primers/chemistry | 10 | 0.0 |
Mucins/genetics/immunology/*metabolism | 2 | 40.0 |
Peptide Fragments/immunology | 6 | 2.0 |
Tears/*metabolism | 2 | 13.0 |
Bile Ducts, Intrahepatic/*pathology | 2 | 25.0 |
CA-15-3 Antigen/analysis/*biosynthesis | 2 | 100.0 |
*Gene Expression Regulation, Neoplastic | 20 | 1.0 |
Peptide Fragments/biosynthesis | 2 | 15.0 |
Adenocarcinoma/*metabolism/mortality/pathology | 2 | 13.0 |
CA-15-3 Antigen/*biosynthesis | 22 | 88.0 |
Protein p53/metabolism | 4 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Receptors, Progesterone/metabolism | 2 | 1.0 |
Tumor Markers, Biological/metabolism | 19 | 4.0 |
CA-15-3 Antigen/analysis/*immunology | 6 | 100.0 |
Epitopes/analysis | 18 | 7.0 |
Carcinoma/metabolism/pathology | 2 | 11.0 |
Gastric Mucosa/metabolism/pathology | 2 | 9.0 |
Gastroscopy | 2 | 4.0 |
Metaplasia/metabolism/pathology | 3 | 37.0 |
Mucins/classification/*metabolism | 3 | 75.0 |
Retrospective Studies | 21 | 0.0 |
Tumor Markers, Biological | 11 | 2.0 |
Neoplasm Proteins/*metabolism | 12 | 2.0 |
Cell Line, Tumor | 19 | 0.0 |
Immunotherapy | 10 | 3.0 |
RNA, Messenger/analysis | 36 | 1.0 |
Alleles | 6 | 0.0 |
Cattle | 7 | 0.0 |
Consensus Sequence | 6 | 0.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Gene Frequency | 3 | 0.0 |
Polymerase Chain Reaction | 27 | 0.0 |
*Polymorphism, Genetic | 8 | 0.0 |
Repetitive Sequences, Nucleic Acid | 28 | 3.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Cell Separation | 3 | 0.0 |
Dose-Response Relationship, Drug | 11 | 0.0 |
Glycoproteins/chemistry | 3 | 11.0 |
Hypersensitivity, Delayed | 3 | 4.0 |
Immunoglobulin G/chemistry | 2 | 8.0 |
Peptides/chemistry | 8 | 2.0 |
Antigens, Neoplasm/*physiology | 3 | 42.0 |
Cadherins/metabolism | 4 | 3.0 |
Cytoskeletal Proteins/*physiology | 2 | 9.0 |
Phosphorylation | 22 | 0.0 |
*Trans-Activators | 9 | 1.0 |
CA-15-3 Antigen | 46 | 51.0 |
Cystic Fibrosis/*metabolism | 3 | 6.0 |
Gene Expression Profiling | 6 | 0.0 |
Immunoblotting | 18 | 0.0 |
Lung/metabolism | 2 | 1.0 |
Microscopy, Fluorescence | 9 | 0.0 |
Mucins/metabolism | 6 | 12.0 |
Oligonucleotides, Antisense/pharmacology | 2 | 0.0 |
Proto-Oncogene Protein pp60(c-src)/*metabolism | 2 | 5.0 |
Up-Regulation | 20 | 0.0 |
Colorectal Neoplasms/*metabolism/pathology | 6 | 12.0 |
CA-19-9 Antigen/analysis | 2 | 15.0 |
Keratin/analysis | 8 | 3.0 |
CA-15-3 Antigen/*immunology | 58 | 98.0 |
Escherichia coli | 3 | 0.0 |
Killer Cells, Lymphokine-Activated/immunology | 4 | 6.0 |
Molecular Weight | 18 | 0.0 |
Protein Folding | 3 | 0.0 |
Adenoma/*metabolism/pathology | 3 | 8.0 |
Carcinoma/*metabolism/pathology | 4 | 6.0 |
Carcinoma in Situ/metabolism/pathology | 3 | 30.0 |
Epithelial Cells/metabolism/pathology | 2 | 4.0 |
Ki-67 Antigen/analysis | 4 | 1.0 |
Cell Membrane/metabolism | 12 | 0.0 |
Epithelium/physiology | 4 | 4.0 |
Cytoskeletal Proteins/genetics/*metabolism | 2 | 3.0 |
Glycogen Synthase Kinase 3 | 3 | 3.0 |
Antibodies, Monoclonal/*immunology/therapeutic use | 2 | 18.0 |
Binding Sites, Antibody | 4 | 1.0 |
CA-15-3 Antigen/genetics/*immunology | 6 | 100.0 |
Epitope Mapping | 9 | 3.0 |
Epitopes/immunology | 11 | 2.0 |
Mice, Inbred BALB C | 28 | 0.0 |
Epithelium/metabolism | 23 | 5.0 |
Gallbladder/*metabolism | 3 | 23.0 |
Mucins/*genetics | 34 | 31.0 |
Epitopes | 21 | 2.0 |
Kidney Neoplasms/*metabolism/pathology | 2 | 6.0 |
Milk/*chemistry | 3 | 20.0 |
Restriction Mapping | 6 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 6 | 0.0 |
Antigens, Neoplasm/immunology | 7 | 5.0 |
Carbohydrates/immunology | 2 | 16.0 |
Colorectal Neoplasms/*immunology/*pathology | 2 | 33.0 |
Lewis Blood-Group System/*immunology | 2 | 22.0 |
Mucins/*immunology | 12 | 54.0 |
Paraffin Embedding | 5 | 1.0 |
Peptides/immunology | 8 | 5.0 |
Breast Neoplasms/*immunology/*therapy | 2 | 100.0 |
Cancer Vaccines/*therapeutic use | 7 | 31.0 |
*Immunotherapy, Active | 4 | 16.0 |
Lymphocyte Activation/drug effects | 3 | 0.0 |
Peptide Fragments/chemistry/*immunology | 3 | 25.0 |
T-Lymphocytes/*immunology | 6 | 0.0 |
Epithelium/chemistry | 7 | 6.0 |
Infant, Newborn | 4 | 0.0 |
Molecular Structure | 4 | 0.0 |
Polymorphism, Genetic | 8 | 0.0 |
Neoplasm Transplantation | 11 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 4 | 0.0 |
Clinical Trials | 6 | 0.0 |
Hemocyanin/*immunology | 2 | 18.0 |
Neoplasms/*therapy | 5 | 4.0 |
Vaccination | 5 | 3.0 |
Vaccines, Conjugate/immunology | 3 | 42.0 |
*Antibody Formation | 2 | 2.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Immunoglobulin M/analysis | 3 | 1.0 |
Parity | 2 | 1.0 |
Pregnancy/*immunology | 2 | 3.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
Adenocarcinoma/*metabolism | 5 | 5.0 |
Antibodies/immunology | 5 | 1.0 |
Carbohydrates/chemistry | 4 | 40.0 |
Glycoproteins/chemistry/isolation & purification | 3 | 60.0 |
Pancreatic Neoplasms/*metabolism | 7 | 9.0 |
RNA, Messenger/biosynthesis | 11 | 0.0 |
Adenocarcinoma/*genetics | 4 | 2.0 |
Chronic Disease | 8 | 0.0 |
Mucins/analysis/*genetics | 5 | 33.0 |
Pancreas/chemistry | 2 | 8.0 |
Pancreatic Neoplasms/*genetics | 2 | 2.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
CA-15-3 Antigen/*physiology | 6 | 100.0 |
Neoplasms/*pathology | 2 | 3.0 |
CA-15-3 Antigen/*analysis | 14 | 82.0 |
Protein p53/analysis | 5 | 1.0 |
Mitogen-Activated Protein Kinases/*metabolism | 3 | 0.0 |
Diagnosis, Differential | 14 | 0.0 |
Intermediate Filament Proteins/analysis | 2 | 5.0 |
Intestines/*pathology | 3 | 23.0 |
Keratin/*analysis | 2 | 6.0 |
CA-15-3 Antigen/*analysis/immunology | 6 | 85.0 |
Immunohistochemistry/methods | 11 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
*Antigen Presentation | 3 | 1.0 |
Antigens, Neoplasm/genetics/*immunology | 3 | 25.0 |
Apoptosis | 5 | 0.0 |
Blood Donors | 2 | 0.0 |
Dendritic Cells/*immunology/metabolism | 3 | 6.0 |
Dose-Response Relationship, Immunologic | 5 | 0.0 |
*Gene Therapy | 3 | 0.0 |
Lymphocyte Culture Test, Mixed | 5 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 3 | 0.0 |
Vaccinia virus/genetics | 2 | 2.0 |
Adenoviridae/genetics | 4 | 0.0 |
Cation Exchange Resins | 2 | 22.0 |
Lipids | 2 | 10.0 |
Liposomes | 3 | 1.0 |
Lymphocyte Activation/immunology | 5 | 0.0 |
Phytohemagglutinins/pharmacology | 4 | 0.0 |
Transfection/*methods | 2 | 3.0 |
*Antigens, CD | 4 | 0.0 |
Cell Movement | 2 | 0.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Prostatic Neoplasms/*genetics/pathology | 2 | 2.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Fluorescent Antibody Technique, Indirect | 7 | 0.0 |
Tumor Markers, Biological/analysis | 10 | 1.0 |
*Antigens, Neoplasm | 3 | 1.0 |
Neoplasm Proteins/*biosynthesis | 3 | 3.0 |
Signal Transduction/physiology | 2 | 0.0 |
Carcinoembryonic Antigen/analysis | 5 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 2 | 0.0 |
Immunization | 16 | 4.0 |
Mucins/*analysis/genetics | 5 | 62.0 |
Neoplasm Proteins/*analysis/genetics | 2 | 4.0 |
Breast Neoplasms/*immunology | 12 | 21.0 |
Cytokines/biosynthesis | 3 | 0.0 |
*Alternative Splicing | 3 | 0.0 |
Hela Cells | 3 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 14 | 1.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Respiratory Mucosa/*metabolism | 2 | 14.0 |
Antigen Presentation/immunology | 2 | 2.0 |
Binding, Competitive | 9 | 0.0 |
CA-15-3 Antigen/chemistry/metabolism | 2 | 100.0 |
Cancer Vaccines/immunology | 3 | 15.0 |
Cytotoxicity Tests, Immunologic | 7 | 1.0 |
Antineoplastic Agents, Hormonal/*pharmacology | 3 | 5.0 |
CA-15-3 Antigen/*biosynthesis/genetics | 7 | 100.0 |
Neoadjuvant Therapy | 2 | 5.0 |
Tamoxifen/*pharmacology | 2 | 3.0 |
Adolescent | 17 | 0.0 |
Case-Control Studies | 11 | 0.0 |
Staining and Labeling/methods | 2 | 1.0 |
Antibodies, Monoclonal/immunology | 18 | 1.0 |
CA-15-3 Antigen/biosynthesis/*immunology | 3 | 100.0 |
Epitopes, T-Lymphocyte/immunology | 3 | 3.0 |
Mammary Neoplasms, Experimental/metabolism | 2 | 25.0 |
CA-15-3 Antigen/genetics | 11 | 78.0 |
Cell Line, Transformed | 4 | 0.0 |
*Gene Expression | 14 | 1.0 |
CA-15-3 Antigen/*analysis/chemistry/immunology | 3 | 100.0 |
Multivariate Analysis | 9 | 0.0 |
Stomach Neoplasms/*chemistry/mortality/pathology | 2 | 20.0 |
Membrane Glycoproteins/*metabolism | 4 | 0.0 |
Antigens, Neoplasm/biosynthesis | 2 | 12.0 |
Breast/*cytology | 2 | 5.0 |
Cell Culture Techniques | 4 | 0.0 |
Antibodies, Monoclonal | 37 | 1.0 |
Antigens, Neoplasm/metabolism | 4 | 5.0 |
Pancreatectomy | 2 | 8.0 |
Biological Markers | 3 | 0.0 |
Microscopy, Immunoelectron | 4 | 0.0 |
Antigens, Neoplasm/*metabolism | 8 | 8.0 |
Cytoskeletal Proteins/*metabolism | 4 | 2.0 |
Receptor, Epidermal Growth Factor/*metabolism | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 3 | 0.0 |
HCT116 Cells | 2 | 8.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Lactation | 2 | 3.0 |
CA-15-3 Antigen/*genetics | 17 | 94.0 |
DNA/genetics | 6 | 0.0 |
Genotype | 5 | 0.0 |
Minisatellite Repeats/genetics | 2 | 4.0 |
Stomach Neoplasms/*genetics | 2 | 1.0 |
Acute Disease | 2 | 0.0 |
Breast Neoplasms/immunology/therapy | 3 | 50.0 |
Minisatellite Repeats | 7 | 5.0 |
Peptide Fragments/*immunology | 11 | 10.0 |
Adenocarcinoma | 3 | 2.0 |
Dogs | 7 | 0.0 |
Kidney | 2 | 0.0 |
Axilla | 6 | 9.0 |
Lymph Nodes/pathology | 4 | 1.0 |
Lymphatic Metastasis/pathology | 3 | 4.0 |
CA-15-3 Antigen/immunology/metabolism | 3 | 100.0 |
Carbohydrate Sequence | 25 | 7.0 |
Oxidation-Reduction | 4 | 0.0 |
Cell Transformation, Neoplastic | 9 | 1.0 |
Child | 10 | 0.0 |
Mucins/analysis/*biosynthesis | 2 | 50.0 |
Cancer Vaccines/pharmacology | 2 | 100.0 |
Models, Biological | 6 | 0.0 |
Signal Transduction | 15 | 0.0 |
Adenocarcinoma, Mucinous/*metabolism/pathology | 4 | 57.0 |
Carcinoma, Pancreatic Ductal/*metabolism/pathology | 3 | 27.0 |
Pancreatic Neoplasms/*metabolism/pathology | 6 | 12.0 |
Staining and Labeling | 3 | 0.0 |
DNA Primers | 17 | 0.0 |
Tumor Markers, Biological/*analysis/genetics | 3 | 8.0 |
Microcirculation | 2 | 0.0 |
Phenotype | 17 | 0.0 |
Breast/cytology/*metabolism | 2 | 8.0 |
Breast Neoplasms/genetics | 3 | 1.0 |
Down-Regulation | 5 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Genes, erbB-2 | 3 | 3.0 |
Genes, ras | 3 | 1.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 4 | 0.0 |
*Signal Transduction | 2 | 0.0 |
Antibodies, Monoclonal/*metabolism | 2 | 5.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Antigens, Tumor-Associated, Carbohydrate/metabolism | 3 | 42.0 |
Binding Sites | 15 | 0.0 |
Epitopes/metabolism | 4 | 7.0 |
Peptides/*metabolism | 5 | 2.0 |
Polysaccharides/metabolism | 3 | 12.0 |
Breast Neoplasms/*diagnosis | 2 | 11.0 |
Immunoassay/*methods | 2 | 2.0 |
Breast Neoplasms/*blood | 3 | 7.0 |
Immunoassay/methods | 2 | 3.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Antigens, Neoplasm/*biosynthesis | 2 | 6.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 3 | 3.0 |
Esophageal Neoplasms/*metabolism/pathology | 3 | 13.0 |
Antibodies, Monoclonal/*therapeutic use | 7 | 2.0 |
B-Lymphocytes/immunology | 5 | 0.0 |
Membrane Glycoproteins/immunology | 3 | 1.0 |
CA-15-3 Antigen/chemistry/genetics/*immunology | 3 | 16.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Killer Cells, Natural/*immunology | 3 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
Repetitive Sequences, Amino Acid | 6 | 4.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
CA-15-3 Antigen/analysis/*genetics | 3 | 100.0 |
CA-15-3 Antigen/administration & dosage/genetics/*immunology | 2 | 100.0 |
Disease-Free Survival | 10 | 1.0 |
Epitopes, T-Lymphocyte/*immunology | 3 | 5.0 |
Immunoglobulin G/biosynthesis | 2 | 1.0 |
Endometrium/metabolism | 2 | 3.0 |
Polysaccharides/*metabolism | 2 | 8.0 |
Rats | 10 | 0.0 |
CA-15-3 Antigen/genetics/metabolism | 6 | 100.0 |
RNA, Messenger/analysis/biosynthesis | 3 | 1.0 |
Biopsy, Needle | 6 | 1.0 |
Carcinoma in Situ/*chemistry | 2 | 50.0 |
Culture Techniques | 4 | 0.0 |
CA-15-3 Antigen/*chemistry/genetics/*metabolism | 2 | 100.0 |
Caco-2 Cells | 3 | 0.0 |
Colon/metabolism | 6 | 5.0 |
Pancreas/metabolism | 4 | 4.0 |
Chromatography, Gel | 6 | 0.0 |
*Radioimmunotherapy | 3 | 11.0 |
Cell Death | 2 | 0.0 |
Cell Survival | 5 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Immunotherapy, Adoptive | 2 | 2.0 |
Tomography, Emission-Computed | 2 | 1.0 |
Cross-Sectional Studies | 2 | 0.0 |
Stomach Neoplasms/*metabolism/mortality/pathology | 2 | 15.0 |
Endometrium/*chemistry | 2 | 8.0 |
Epithelial Cells/chemistry | 3 | 8.0 |
Fallopian Tubes/*chemistry | 2 | 28.0 |
Fluorescent Antibody Technique | 9 | 0.0 |
Histocytochemistry | 3 | 0.0 |
Neuraminidase/pharmacology | 5 | 7.0 |
Epithelial Cells | 5 | 1.0 |
Organ Specificity | 8 | 0.0 |
Promoter Regions (Genetics) | 7 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Detergents | 2 | 1.0 |
Mouth Mucosa/*metabolism | 3 | 33.0 |
Submandibular Gland/metabolism | 2 | 14.0 |
Antibodies, Monoclonal/*diagnostic use | 2 | 0.0 |
Mice, Nude | 14 | 0.0 |
Radioimmunodetection/*methods | 2 | 20.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Mucins/*genetics/*metabolism | 6 | 75.0 |
Respiratory Mucosa/metabolism/pathology | 2 | 28.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Collagen/metabolism | 2 | 0.0 |
Cytoskeletal Proteins/metabolism | 7 | 2.0 |
Radioimmunoassay | 3 | 0.0 |
Tyrosine/metabolism | 7 | 0.0 |
Adenocarcinoma/metabolism | 5 | 7.0 |
Biopsy | 5 | 0.0 |
CA-15-3 Antigen/chemistry | 2 | 100.0 |
Interferon Type II/biosynthesis | 4 | 0.0 |
Adoptive Transfer | 4 | 5.0 |
CA-15-3 Antigen/*chemistry | 4 | 80.0 |
Interferon Type II/metabolism | 2 | 0.0 |
Receptors, Antigen, T-Cell/metabolism | 3 | 1.0 |
Microscopy, Electron | 6 | 0.0 |
Models, Genetic | 2 | 0.0 |
N-Acetylneuraminic Acid/metabolism | 2 | 13.0 |
Neuraminidase/metabolism | 3 | 9.0 |
Adenocarcinoma/*metabolism/pathology | 4 | 3.0 |
Breast | 3 | 9.0 |
Disease Models, Animal | 8 | 0.0 |
Glycoproteins/metabolism | 5 | 3.0 |
RNA/analysis | 4 | 1.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Statistics, Nonparametric | 3 | 0.0 |
Embryo Implantation/immunology | 2 | 28.0 |
Mice, Knockout | 4 | 0.0 |
Receptor, erbB-2/metabolism | 6 | 3.0 |
Mucins/*genetics/metabolism | 10 | 35.0 |
*Promoter Regions (Genetics) | 7 | 0.0 |
RNA, Messenger/genetics | 13 | 0.0 |
TATA Box | 2 | 0.0 |
Transcription, Genetic | 14 | 0.0 |
Automation | 2 | 3.0 |
Breast Neoplasms/*blood/diagnosis | 2 | 40.0 |
Adenocarcinoma/*chemistry/pathology | 2 | 4.0 |
Colonic Neoplasms/immunology/therapy | 2 | 50.0 |
Neoplasms/immunology/*therapy | 4 | 7.0 |
Recombinant Fusion Proteins/administration & dosage/immunology | 2 | 33.0 |
Breast/metabolism | 4 | 4.0 |
Cross Reactions | 7 | 0.0 |
*Lectins, C-Type | 4 | 2.0 |
*Mannose-Binding Lectins | 4 | 8.0 |
Receptors, Cell Surface/immunology | 2 | 5.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Precancerous Conditions/*metabolism/pathology | 3 | 14.0 |
Tumor Markers, Biological/biosynthesis | 2 | 5.0 |
Culture Media | 2 | 0.0 |
Cell Adhesion/physiology | 7 | 2.0 |
Neoplasms/metabolism/therapy | 2 | 40.0 |
Neoplasm Metastasis | 15 | 1.0 |
Cell Adhesion Molecules/*metabolism | 3 | 1.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Blotting, Southern | 9 | 0.0 |
Antibody Specificity/immunology | 5 | 7.0 |
Epitopes/*immunology | 8 | 3.0 |
Mucins/immunology | 3 | 27.0 |
Neoplasms/*immunology | 6 | 5.0 |
CA-15-3 Antigen/*immunology/pharmacology | 2 | 100.0 |
Neoplasm Metastasis/*immunology | 2 | 15.0 |
Extracellular Matrix/physiology | 2 | 2.0 |
Epitopes, T-Lymphocyte/*immunology/metabolism | 2 | 28.0 |
Peptide Fragments/*immunology/metabolism | 2 | 16.0 |
T-Lymphocytes, Cytotoxic/*immunology/metabolism | 3 | 8.0 |
Coculture Techniques | 3 | 0.0 |
Endometrium/*metabolism | 3 | 3.0 |
Peptide Fragments/*biosynthesis | 3 | 33.0 |
Progesterone/*pharmacology | 3 | 3.0 |
Antigens, Tumor-Associated, Carbohydrate/*metabolism | 4 | 21.0 |
Keratin/*metabolism | 5 | 15.0 |
Chromosome Mapping | 3 | 0.0 |
*Chromosomes, Human, Pair 1 | 4 | 0.0 |
*Chromosomes, Human, Pair 14 | 2 | 1.0 |
Gene Rearrangement | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
*Translocation, Genetic | 2 | 0.0 |
CA-15-3 Antigen/biosynthesis/genetics | 2 | 66.0 |
Lung Neoplasms/*metabolism/pathology | 4 | 5.0 |
Mucins/*biosynthesis/genetics | 7 | 31.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Glycogen Synthase Kinases | 2 | 3.0 |
Protein-Tyrosine Kinase/*physiology | 2 | 1.0 |
Protein p53/genetics/metabolism | 2 | 2.0 |
Breast Neoplasms/immunology/metabolism | 3 | 100.0 |
CA-15-3 Antigen/immunology/*metabolism | 8 | 100.0 |
Sialyltransferases/immunology/*metabolism | 2 | 100.0 |
Image Processing, Computer-Assisted | 3 | 0.0 |
CD8-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Cell Division/immunology | 2 | 0.0 |
Cell Fusion | 2 | 0.0 |
Lymph Nodes/immunology | 3 | 3.0 |
Gene Therapy | 2 | 0.0 |
Vaccines/immunology | 3 | 50.0 |
*Bile Ducts, Intrahepatic | 4 | 12.0 |
Risk Factors | 4 | 0.0 |
Gestational Age | 5 | 0.0 |
Pancreas/*metabolism | 3 | 8.0 |
Metaplasia | 4 | 4.0 |
Stomach/embryology/*metabolism/pathology | 2 | 100.0 |
Stomach Neoplasms/*metabolism | 3 | 6.0 |
Ovarian Neoplasms/*immunology | 2 | 6.0 |
Periodic Acid/pharmacology | 2 | 18.0 |
Adenocarcinoma/*genetics/metabolism | 3 | 7.0 |
Cell Differentiation/genetics | 3 | 1.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Barrett Esophagus/genetics/*metabolism | 2 | 100.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology/metabolism | 4 | 28.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Recurrence | 3 | 0.0 |
Antibodies, Blocking/pharmacology | 3 | 3.0 |
Antigen Presentation/drug effects/*immunology | 2 | 66.0 |
*Immune Tolerance | 2 | 1.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Vaccinia virus/*immunology | 2 | 22.0 |
*Cancer Vaccines | 5 | 19.0 |
Dendritic Cells/cytology/*immunology | 3 | 5.0 |
Gene Therapy/*methods | 2 | 0.0 |
Antigens, Neoplasm/*genetics | 3 | 4.0 |
Tumor Cells, Cultured/immunology | 2 | 2.0 |
Cell Adhesion/immunology | 2 | 1.0 |
HL-60 Cells | 2 | 0.0 |
Hematopoietic Stem Cells/*metabolism | 2 | 1.0 |
Breast Diseases/blood | 3 | 50.0 |
RNA, Messenger/blood | 2 | 3.0 |
RNA, Neoplasm/blood | 2 | 33.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
K562 Cells | 2 | 0.0 |
Antigens, CD15/analysis | 2 | 7.0 |
CA-15-3 Antigen/*isolation & purification | 2 | 100.0 |
Lewis Blood-Group System/analysis | 2 | 40.0 |
Culture Media, Conditioned | 2 | 0.0 |
Antibodies/*immunology | 2 | 1.0 |
CA-15-3 Antigen/genetics/immunology | 2 | 100.0 |
Chick Embryo | 2 | 0.0 |
*Genetic Vectors | 2 | 0.0 |
Histocompatibility Antigens Class I/*immunology | 2 | 1.0 |
Mannans/*immunology | 4 | 57.0 |
Mice, Inbred DBA | 6 | 1.0 |
Digestive Physiology | 2 | 8.0 |
Exons | 4 | 0.0 |
Age Factors | 5 | 0.0 |
Stomach Neoplasms | 2 | 6.0 |
Conjunctiva/*chemistry | 2 | 40.0 |
Tears/*chemistry | 2 | 11.0 |
Immunoglobulin G/blood/immunology | 2 | 4.0 |
Antigens, Neoplasm/*administration & dosage/genetics/immunology | 2 | 100.0 |
CA-15-3 Antigen/administration & dosage/genetics/pharmacology | 2 | 100.0 |
CD40 Ligand/genetics/metabolism/therapeutic use | 2 | 100.0 |
CD8-Positive T-Lymphocytes/drug effects/immunology | 2 | 8.0 |
Cancer Vaccines/*genetics/immunology/*pharmacology | 2 | 100.0 |
Cell Survival/drug effects | 4 | 0.0 |
Chemotaxis/drug effects | 2 | 2.0 |
Clonal Anergy/*drug effects/immunology | 2 | 100.0 |
Dendritic Cells/drug effects/metabolism/physiology | 2 | 100.0 |
Genetic Vectors/therapeutic use | 2 | 33.0 |
Neoplasms, Experimental/pathology/therapy | 2 | 100.0 |
Oncogene Proteins, Viral/administration & dosage/genetics/pharmacology | 2 | 100.0 |
Papillomavirus | 2 | 25.0 |
Peptide Fragments/administration & dosage/genetics/pharmacology | 2 | 100.0 |
Receptors, Chemokine/biosynthesis | 2 | 4.0 |
Recombinant Fusion Proteins/administration & dosage/genetics/pharmacology | 2 | 100.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Karyotyping | 4 | 0.0 |
Multigene Family | 2 | 0.0 |
Liver Neoplasms/*secondary | 2 | 10.0 |
*Neoplasm Circulating Cells | 2 | 5.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 3 | 1.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Mucins/analysis/*immunology | 2 | 100.0 |
Interleukin-2/metabolism | 2 | 1.0 |
Leukocytes, Mononuclear/drug effects/immunology/metabolism | 2 | 14.0 |
Mannans/immunology | 6 | 75.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Adenocarcinoma/pathology | 2 | 2.0 |
Breast Neoplasms/pathology | 2 | 1.0 |
Gene Expression Regulation/*drug effects | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism/pathology | 2 | 5.0 |
Incidence | 3 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/*immunology | 3 | 15.0 |
Tumor Markers, Biological/immunology | 2 | 11.0 |
Transplantation, Heterologous | 10 | 1.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Growth Substances/*metabolism | 2 | 1.0 |
*Muscle Proteins | 5 | 1.0 |
*Neuropeptides | 5 | 4.0 |
Stomach Neoplasms/*metabolism/pathology | 7 | 12.0 |
Biological Markers/blood | 3 | 0.0 |
Ovarian Neoplasms/blood/*immunology | 2 | 50.0 |
Autoantibodies/*blood | 3 | 1.0 |
Adenocarcinoma/metabolism/*pathology | 3 | 5.0 |
Colonic Neoplasms/metabolism/*pathology | 2 | 8.0 |
*Proteins | 3 | 0.0 |
*Tumor Markers, Biological | 4 | 2.0 |
Antibodies, Neoplasm/*immunology/isolation & purification | 2 | 100.0 |
Centrifugation, Density Gradient | 6 | 1.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Antibodies, Neoplasm/*biosynthesis | 2 | 25.0 |
Antibody Formation/immunology | 2 | 4.0 |
CA-15-3 Antigen/chemistry/*immunology/metabolism | 2 | 100.0 |
Fluorescence | 2 | 0.0 |
H-2 Antigens/genetics/immunology | 2 | 20.0 |
Peptide Fragments/chemistry/*immunology/metabolism | 2 | 100.0 |
Epithelium/metabolism/pathology | 2 | 3.0 |
Antigens/immunology/*metabolism | 2 | 50.0 |
Glycoproteins/immunology/*metabolism | 2 | 11.0 |
Antibodies, Neoplasm/blood | 2 | 40.0 |
Neoplasm Proteins/genetics/*metabolism | 3 | 1.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Antibodies, Monoclonal/pharmacology | 7 | 0.0 |
Colorectal Neoplasms/*chemistry | 2 | 16.0 |
Solubility | 5 | 0.0 |
Cadherins/*biosynthesis | 3 | 9.0 |
Antibodies, Bispecific/*therapeutic use | 2 | 20.0 |
Neoplasms, Experimental/therapy | 2 | 14.0 |
Antigens, Tumor-Associated, Carbohydrate/*biosynthesis | 2 | 25.0 |
Carcinoma/*metabolism | 5 | 6.0 |
Barrett Esophagus/*metabolism/pathology | 2 | 25.0 |
CA-15-3 Antigen/analysis/*metabolism | 4 | 100.0 |
Mucins/analysis/*metabolism | 2 | 66.0 |
Enzyme Activation | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 3/metabolism | 2 | 5.0 |
Recombinant Proteins | 3 | 0.0 |
Bile Duct Neoplasms/*metabolism | 2 | 33.0 |
Iodine Radioisotopes/*therapeutic use | 2 | 6.0 |
Multiple Myeloma/metabolism/*radiotherapy | 2 | 100.0 |
Bile Duct Neoplasms/*classification/diagnosis/metabolism/pathology | 2 | 100.0 |
*Bile Ducts, Intrahepatic/metabolism/pathology | 2 | 100.0 |
Cholangiocarcinoma/*classification/diagnosis/metabolism/pathology | 2 | 100.0 |
Statistics | 2 | 0.0 |
Clinical Trials, Phase I | 2 | 3.0 |
Colonic Neoplasms/metabolism | 3 | 5.0 |
Immunotherapy/methods | 5 | 6.0 |
Neoplasms/immunology/*metabolism/therapy | 2 | 66.0 |
Peptide Fragments/genetics/immunology/*metabolism | 2 | 66.0 |
Glycoproteins/biosynthesis | 3 | 10.0 |
Apoptosis/drug effects | 2 | 0.0 |
Breast Neoplasms/*genetics/metabolism | 3 | 2.0 |
Neoplasm Proteins/biosynthesis/*genetics | 2 | 2.0 |
Sequence Deletion | 6 | 0.0 |
Transcription Factors/metabolism | 4 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 3 | 1.0 |
Breast Neoplasms/*enzymology | 3 | 4.0 |
Sialyltransferases/genetics/*metabolism | 2 | 33.0 |
Breast Neoplasms/chemistry/*pathology | 2 | 11.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
CA-125 Antigen/analysis | 2 | 10.0 |
Epithelial Cells/immunology | 2 | 5.0 |
Keratin/*biosynthesis | 2 | 20.0 |
Epitopes, B-Lymphocyte/immunology | 2 | 12.0 |
Glycoproteins/immunology | 2 | 2.0 |
Neoplasms/*immunology/pathology | 2 | 15.0 |
*Molecular Mimicry | 2 | 5.0 |
Swine | 3 | 0.0 |
Breast Neoplasms/*chemistry | 2 | 2.0 |
Hyperplasia | 5 | 1.0 |
Conjunctiva/*physiology | 2 | 100.0 |
Epithelium, Corneal/*physiology | 3 | 75.0 |
Peptides | 2 | 3.0 |
Antigens, CD3/immunology | 3 | 1.0 |
CA-15-3 Antigen/analysis/genetics | 3 | 75.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Child, Preschool | 4 | 0.0 |
Gallbladder/*metabolism/pathology | 2 | 66.0 |
Infant | 6 | 0.0 |
Mucins/biosynthesis | 2 | 16.0 |
Neoplasm Proteins/biosynthesis | 4 | 5.0 |
Antibodies, Neoplasm/immunology | 6 | 16.0 |
CA-15-3 Antigen/chemistry/genetics/*metabolism | 4 | 100.0 |
Oligosaccharides/immunology | 2 | 50.0 |
Pancreatic Neoplasms | 3 | 7.0 |
Gene Expression/drug effects | 3 | 0.0 |
Intestinal Mucosa/metabolism | 3 | 2.0 |
DNA Mutational Analysis | 4 | 0.0 |
Cancer Vaccines/administration & dosage/immunology | 2 | 100.0 |
Drug Carriers | 2 | 1.0 |
Oligodeoxyribonucleotides/chemistry | 2 | 0.0 |
Stomach Neoplasms/metabolism/*pathology | 2 | 6.0 |
Ploidies | 2 | 0.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
T-Lymphocyte Subsets/*immunology | 2 | 0.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Carbohydrates/*immunology | 3 | 30.0 |
Disaccharides/immunology | 2 | 22.0 |
Peptides/*immunology | 3 | 4.0 |
Colon/*metabolism | 3 | 5.0 |
Polyps/*metabolism/pathology | 2 | 40.0 |
Carcinoma, Ductal, Breast/*metabolism | 2 | 18.0 |
Macaca fascicularis | 2 | 0.0 |
Antigens, CD58/biosynthesis | 2 | 28.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 2 | 2.0 |
Fatal Outcome | 3 | 0.0 |
Colonic Neoplasms/*genetics/pathology | 3 | 6.0 |
Liver Neoplasms/*chemistry | 2 | 8.0 |
Precancerous Conditions/*chemistry | 2 | 28.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Antigen Presentation/*immunology | 2 | 2.0 |
Antigen-Presenting Cells/immunology | 3 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 2 | 3.0 |
Breast Neoplasms/blood | 2 | 9.0 |
Epithelial Cells/cytology/physiology | 2 | 6.0 |
Breast Neoplasms/immunology | 10 | 29.0 |
Receptors, Antigen, T-Cell/immunology | 3 | 1.0 |
CA-15-3 Antigen/blood/*immunology | 2 | 100.0 |
*Tandem Repeat Sequences | 3 | 2.0 |
Gastric Mucosa/metabolism | 3 | 6.0 |
Regression Analysis | 2 | 0.0 |
Reproducibility of Results | 4 | 0.0 |
Epitopes/chemistry/metabolism | 2 | 20.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Temperature | 3 | 0.0 |
Thermodynamics | 2 | 0.0 |
Titrimetry | 2 | 6.0 |
Tyrosine/chemistry | 2 | 1.0 |
RNA, Messenger/*analysis | 7 | 1.0 |
*Vaccination | 3 | 5.0 |
Acetylgalactosamine/*metabolism | 2 | 28.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Substrate Specificity | 6 | 0.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
Tretinoin/pharmacology | 3 | 0.0 |
Oligosaccharides/chemistry/immunology | 2 | 33.0 |
Protein Engineering | 2 | 2.0 |
Intestinal Mucosa/*metabolism | 3 | 3.0 |
Lung Neoplasms/*metabolism | 3 | 3.0 |
Respiratory System/*metabolism | 2 | 14.0 |
Stomach Neoplasms/immunology | 2 | 16.0 |
Mucins/genetics/*immunology | 5 | 100.0 |
Melanoma, Experimental/*immunology | 2 | 28.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology | 2 | 8.0 |
Receptor, Epidermal Growth Factor/metabolism | 3 | 0.0 |
DNA Probes | 5 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
*CA-15-3 Antigen | 4 | 100.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism | 2 | 3.0 |
Lymphocyte Activation/*immunology | 3 | 0.0 |
*Peptide Fragments | 3 | 21.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
Oligonucleotide Probes | 3 | 0.0 |
Embryo Implantation/physiology | 3 | 27.0 |
Menstrual Cycle/physiology | 2 | 5.0 |
Carcinoma, Ductal, Breast/metabolism/pathology | 2 | 9.0 |
Gene Amplification | 2 | 0.0 |
Intercellular Adhesion Molecule-1/*metabolism | 3 | 5.0 |
Carcinoma, Lobular/immunology/pathology | 2 | 40.0 |
Pilot Projects | 2 | 0.0 |
Cohort Studies | 4 | 0.0 |
Lymph Nodes/*pathology | 3 | 3.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Ovary/metabolism | 2 | 2.0 |
Cytoplasm/chemistry | 3 | 1.0 |
Mucins/*analysis/chemistry | 2 | 66.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Lineage | 4 | 0.0 |
Glycoproteins/*immunology | 4 | 5.0 |
*Antibodies, Monoclonal | 5 | 2.0 |
Antigens, Neoplasm/*chemistry/immunology | 2 | 100.0 |
Cytokines/metabolism | 3 | 0.0 |
Histocompatibility Antigens Class II/*immunology | 2 | 1.0 |
Threonine/metabolism | 2 | 2.0 |
Antibodies | 5 | 1.0 |
Uterus/*metabolism | 2 | 4.0 |
CA-15-3 Antigen/chemistry/*metabolism | 5 | 100.0 |
Spectrometry, Mass, Fast Atom Bombardment | 2 | 7.0 |
DNA/biosynthesis | 2 | 0.0 |
Neoplasms/metabolism | 2 | 2.0 |
Colonic Neoplasms/chemistry/pathology | 2 | 40.0 |
Immunoglobulin Variable Region | 2 | 8.0 |
Peptide Library | 3 | 2.0 |
T-Lymphocytes/drug effects/*immunology | 2 | 1.0 |
Adenocarcinoma/metabolism/pathology | 2 | 3.0 |
Breast Neoplasms/metabolism/pathology | 3 | 7.0 |
CA-15-3 Antigen/*analysis/physiology | 3 | 100.0 |
Pancreatic Neoplasms/metabolism/pathology | 2 | 33.0 |
Lectins/*metabolism | 2 | 3.0 |
Adenocarcinoma, Mucinous/genetics/*metabolism/pathology | 2 | 66.0 |
Genes, p53 | 2 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Amino Acid Motifs | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Embryo Implantation/*physiology | 2 | 5.0 |
Proteoglycans/*physiology | 2 | 16.0 |
Acetylgalactosamine/*analogs & derivatives/pharmacology | 2 | 100.0 |
Colonic Neoplasms | 4 | 2.0 |
Glycosyltransferases/metabolism | 2 | 28.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Sialic Acids/metabolism | 2 | 8.0 |
CA-15-3 Antigen/*blood/immunology | 2 | 100.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Glycoproteins/*analysis | 2 | 2.0 |
Antibodies, Neoplasm/*blood | 2 | 22.0 |
CA-15-3 Antigen/chemistry/*genetics/metabolism | 2 | 100.0 |
Dipeptides/pharmacology | 2 | 4.0 |
Epithelial Cells/cytology/drug effects/*physiology | 2 | 25.0 |
Hydroxamic Acids/pharmacology | 2 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
CA-15-3 Antigen/*immunology/metabolism | 3 | 100.0 |
Breast/*metabolism | 2 | 3.0 |
Tears/*physiology | 2 | 66.0 |
RNA-Directed DNA Polymerase | 3 | 2.0 |
Plasmids | 3 | 0.0 |
Antibodies, Monoclonal/immunology/metabolism | 2 | 4.0 |
*Cell Adhesion | 3 | 1.0 |
Ovarian Neoplasms/*metabolism | 4 | 6.0 |
Keratin/genetics | 2 | 4.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Tumor Markers, Biological/*genetics | 2 | 1.0 |
Amino Acids/analysis | 3 | 1.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Severity of Illness Index | 2 | 0.0 |
Antibodies, Neoplasm/analysis | 4 | 14.0 |
Drug Synergism | 3 | 0.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
CA-125 Antigen/immunology | 2 | 66.0 |
Bile Ducts, Intrahepatic/metabolism | 2 | 100.0 |
Mucins/chemistry/*metabolism | 2 | 25.0 |
Disaccharides/*immunology | 2 | 11.0 |
Mice, Mutant Strains | 2 | 0.0 |
Adenocarcinoma/*immunology/pathology | 2 | 10.0 |
Antigens, Neoplasm/*analysis | 4 | 1.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Simplexvirus/enzymology/genetics | 2 | 22.0 |
Liver Neoplasms/secondary | 2 | 3.0 |
Antibodies, Monoclonal/*analysis | 12 | 27.0 |
Chromatography, Affinity | 2 | 0.0 |
Ovarian Neoplasms/immunology | 3 | 27.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Colonic Neoplasms/*immunology | 3 | 12.0 |
Immunoradiometric Assay/methods | 2 | 14.0 |
Acetylgalactosamine/*immunology | 2 | 66.0 |
Glycopeptides/*immunology | 4 | 100.0 |
Antibody Specificity/*immunology | 3 | 11.0 |
Rabbits | 7 | 0.0 |
Colon/*immunology | 2 | 9.0 |
Antibody Affinity/immunology | 2 | 12.0 |
Binding Sites, Antibody/*immunology | 3 | 50.0 |
*Epitope Mapping | 4 | 7.0 |
Immunodominant Epitopes/*immunology | 3 | 10.0 |
Pancreatic Neoplasms/*chemistry/pathology | 2 | 22.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Colorectal Neoplasms/metabolism | 2 | 13.0 |
Bronchi/*metabolism | 3 | 9.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Precancerous Conditions/metabolism | 2 | 12.0 |
Interleukin-1/pharmacology | 2 | 0.0 |
Proportional Hazards Models | 3 | 0.0 |
Colonic Neoplasms/*metabolism/pathology | 2 | 5.0 |
N-Acetylgalactosaminyltransferases/isolation & purification/*metabolism | 2 | 100.0 |
Progesterone/pharmacology | 2 | 1.0 |
CA-15-3 Antigen/biosynthesis/*physiology | 2 | 100.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
Carcinoma/*immunology | 2 | 6.0 |
Immunophenotyping | 5 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Luciferases/genetics | 2 | 0.0 |
Glycoproteins/chemistry/*metabolism | 2 | 16.0 |
Sialoglycoproteins/chemistry/*metabolism | 2 | 66.0 |
Multiple Myeloma/*immunology | 2 | 5.0 |
*Transcription, Genetic | 4 | 0.0 |
Gangliosides/immunology/*metabolism | 2 | 100.0 |
Breast Neoplasms/immunology/pathology | 2 | 16.0 |
Epitopes/chemistry/immunology | 2 | 4.0 |
CHO Cells/metabolism | 2 | 5.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Colorectal Neoplasms/metabolism/*pathology | 2 | 9.0 |
Breast Neoplasms/immunology/*therapy | 2 | 33.0 |
Vaccines, Synthetic/immunology | 2 | 6.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Tumor Cells, Cultured/metabolism | 3 | 1.0 |
Kidney/metabolism | 2 | 0.0 |
Mucins/*chemistry | 2 | 11.0 |
Pancreatic Neoplasms/*therapy | 2 | 22.0 |
Ligands | 2 | 0.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Sialic Acids/analysis | 4 | 18.0 |
Tissue Distribution | 7 | 0.0 |
HT29 Cells | 2 | 1.0 |
Methotrexate/*pharmacology | 2 | 4.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/immunology | 2 | 50.0 |
Cytoplasm | 2 | 3.0 |
Abortion, Habitual/*metabolism | 2 | 66.0 |
Epithelium/secretion | 2 | 20.0 |
Keratin/metabolism | 3 | 2.0 |
Mucins/*genetics/immunology | 2 | 66.0 |
Neoplasm Proteins/*genetics | 5 | 0.0 |
N-Acetylneuraminic Acid | 2 | 5.0 |
*Minisatellite Repeats | 2 | 2.0 |
Colonic Neoplasms/*metabolism | 2 | 2.0 |
Introns | 2 | 0.0 |
Colonic Neoplasms/genetics | 2 | 3.0 |
CA-15-3 Antigen/*biosynthesis/*genetics | 3 | 100.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/immunology | 2 | 4.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Gallbladder/metabolism | 2 | 40.0 |
Antigens, Neoplasm/*blood | 2 | 4.0 |
*Gastric Mucin | 4 | 50.0 |
Adenocarcinoma/genetics/metabolism | 2 | 10.0 |
Cluster Analysis | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Conjunctiva/cytology/*metabolism | 2 | 40.0 |
Cornea/cytology/*metabolism | 2 | 16.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 2 | 3.0 |
Breast Neoplasms | 3 | 1.0 |
Mucins/*chemistry/metabolism | 2 | 28.0 |
Antigens/genetics | 2 | 16.0 |
CA-15-3 Antigen/genetics/*physiology | 3 | 100.0 |
Antigens/*metabolism | 2 | 10.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Breast Neoplasms/*chemistry/mortality/pathology | 2 | 10.0 |
Receptors, Estrogen/analysis | 4 | 1.0 |
Membrane Glycoproteins/*physiology | 2 | 0.0 |
Neoplasm Proteins/*physiology | 2 | 2.0 |
Antigen-Antibody Complex/immunology | 2 | 3.0 |
Mucins/*biosynthesis/genetics/isolation & purification | 3 | 75.0 |
Receptor, erbB-2/analysis | 2 | 2.0 |
Receptors, Progesterone/analysis | 2 | 0.0 |
Luciferases/metabolism | 2 | 0.0 |
Microscopy, Phase-Contrast | 2 | 2.0 |
Membrane Glycoproteins/genetics/*immunology | 3 | 5.0 |
*Transfection | 2 | 0.0 |
Mucins/immunology/*metabolism | 2 | 50.0 |
T-Lymphocyte Subsets/immunology | 2 | 0.0 |
N-Acetylgalactosaminyltransferases/metabolism | 2 | 33.0 |
Benzyl Compounds/pharmacology | 2 | 25.0 |
Pancreatic Neoplasms/*pathology | 2 | 5.0 |
Membrane Glycoproteins/*genetics | 5 | 1.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Membrane Glycoproteins/*blood | 4 | 7.0 |
Mucins/*blood | 4 | 80.0 |
Mucins/genetics | 3 | 15.0 |
Cystic Fibrosis Transmembrane Conductance Regulator | 3 | 2.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Antibodies, Monoclonal/*biosynthesis | 2 | 5.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Trans-Activators/metabolism | 4 | 0.0 |
Neoplasm Circulating Cells/*metabolism | 2 | 22.0 |
Fluorescein-5-isothiocyanate | 2 | 1.0 |
Fluorescent Dyes | 2 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Neoplasm Proteins/*blood/immunology | 2 | 66.0 |
Neck | 2 | 3.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Gene Expression/*genetics | 3 | 2.0 |
Epithelial Cells/*metabolism | 6 | 4.0 |
Respiratory System/metabolism | 2 | 20.0 |
CA-125 Antigen/*genetics/metabolism | 2 | 66.0 |
Conjunctiva/*cytology | 2 | 28.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Colonic Neoplasms/*immunology/metabolism | 2 | 66.0 |
Carcinoma, Ductal, Breast/*immunology/mortality/pathology | 2 | 100.0 |
Adenocarcinoma/classification/*metabolism/pathology | 3 | 60.0 |
Mice, Inbred C3H | 2 | 0.0 |
Cell Polarity | 2 | 1.0 |
Peritoneal Neoplasms/secondary | 2 | 14.0 |
Antibodies, Monoclonal/*chemistry | 2 | 5.0 |
Histocompatibility Antigens Class II/metabolism | 3 | 3.0 |
Epitopes/*metabolism | 2 | 10.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
*Proto-Oncogene Proteins | 2 | 0.0 |
Interleukin-7/*pharmacology | 2 | 4.0 |
Multiple Myeloma/*metabolism | 2 | 7.0 |
Protein Transport | 2 | 0.0 |
src-Family Kinases/metabolism | 2 | 1.0 |
Lectins | 2 | 2.0 |
Killer Cells, Natural/immunology | 2 | 0.0 |
Chromosome Breakage/genetics | 2 | 3.0 |
Chromosome Painting/methods | 2 | 25.0 |
Chromosomes, Human, Pair 1/*genetics | 2 | 0.0 |
*Antibody Specificity | 2 | 2.0 |
Histocompatibility Antigens Class I/metabolism | 2 | 3.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Biological Transport | 2 | 0.0 |
